GMAB Genmab Earnings and EPS analysis

EPS in 2026 (TTM): $1.33

Last Report Period Date: Mar 31, 2026

Based on the company's latest reports for March 2026, the current 12-month EPS is $1.33. Genmab's earnings per share in 2025 was reported at $1.55, marking a decline from $1.77 in 2024. In the quarterly report ending on Mar 31, 2026, GMAB's earnings per share amounted to $0.08.

Genmab had an yealy earnings per share of $1.55, showing a decline of 12.4% from $1.77 recorded in 2024. The quarterly earnings per share for the period ending Mar 31, 2026, was $0.08, showing a 74.2% decline compared to the same quarter last year. The trailing twelve months EPS for GMAB is $1.33 as of March 2026. Genmab's full-year EPS for 2024 was $1.77, a 82.5% rise compared to the previous year.

Genmab has recorded a decline in earnings per share of 74.2% in the past 12 months (YoY, quarterly). Over an extended period, the company registered an average EPS annual growth rate of 10.5% per year during the last 3 years. Genmab had an average annual EPS growth of 8.7% in the last five years.